Handelsavisen
prelaunch
Companies Healthcare 0239.HK
02
0239.HK HKEX Pharmaceuticals

Pak Fah Yeow International Ltd

HK$2,43
Open in Charts → Attach watcher ⌖
HKD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
757,3M HKD
P/E
8,3x
EV / Rev
Div yield
2,72 %
Op margin
ROE
Net margin
Debt / equity
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

Pak Fah Yeow International Ltd operates in the pharmaceuticals industry, focusing on the development and distribution of healthcare products.

Business. Pak Fah Yeow International Ltd (0239.HK) is a pharmaceutical company engaged in the research, development, and commercialization of healthcare products. The firm is headquartered in Hong Kong and is primarily listed on the Hong Kong Stock Exchange. As specific operating segment and geographic data are not provided, the company is described at the industry level within the Pharmaceuticals & Medical Research sector. Its business model centers on product sales within the broader healthcare industry.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
ActivityPharmaceuticals & Medical Research
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
8,3x
P/E
Analysts
not yet wired
Ownership
not yet wired
Profitability
not yet wired
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 0239.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 0239.HK. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Pak Fah Yeow International Ltd (0239.HK) is a pharmaceutical company engaged in the research, development, and commercialization of healthcare products. The firm is headquartered in Hong Kong and is primarily listed on the Hong Kong Stock Exchange. As specific operating segment and geographic data are not provided, the company is described at the industry level within the Pharmaceuticals & Medical Research sector. Its business model centers on product sales within the broader healthcare industry.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryPharmaceuticals
    ActivityPharmaceuticals & Medical Research
    AI synthesis
    GENERATED

    Pak Fah Yeow International Ltd has a market capitalization of 757,285,200 HKD, with a market price of 2.43 HKD per share. The company's capital structure is characterized by a lack of dilution risk, as shares outstanding remain unchanged between basic and diluted counts at 311,640,000. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents.

    Profitability metrics indicate a challenging financial position, with the company reporting a negative EPS of -0.06 HKD in the latest period. This suggests that the company is currently unprofitable and may be struggling to generate returns for shareholders. The revenue of 113,802,000 HKD reflects the company's scale of operations, but without comparative industry metrics, it is difficult to assess its relative performance.

    The company's geographic and segment exposure is not disclosed in the available data, making it difficult to assess revenue concentration or diversification. This lack of transparency could pose a risk to investors seeking to understand the company's exposure to regional or product-specific downturns.

    Looking ahead, the company's growth trajectory is unclear. The latest actual revenue of 113,802,000 HKD does not provide a clear indication of future performance, and no forward-looking guidance is available. The absence of analyst estimates or projections further limits the ability to assess the company's potential for growth.

    Risk factors include the inability to assess liquidity risk, which could impact the company's ability to meet short-term obligations. The company is also at risk of continued unprofitability, as evidenced by the negative EPS. There is no indication of dilution risk in the near term, as shares outstanding remain unchanged.

    Recent events and filings do not provide additional insight into the company's operations or strategic direction. The lack of detailed disclosures in source documents limits the ability to form a comprehensive view of the company's current status and future prospects.

    Key takeaways
    • The company is currently unprofitable, with a negative EPS of -0.06 HKD.
    • Market capitalization stands at 757,285,200 HKD, with no dilution risk identified.
    • Liquidity risk could not be assessed due to missing balance-sheet data.
    • Revenue of 113,802,000 HKD provides limited insight into the company's scale and performance.
    • No forward-looking guidance or analyst estimates are available to assess growth potential.
    • The company's geographic and segment exposure is not disclosed, limiting understanding of diversification.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Annual
    ANNUALFiled 2009-04-22
    FY 2009 · Full-year highlights

    Revenue HK$213.9M, −9,7% YoY; Operating income +9,9% YoY.

    RevenueHK$213.9M−9,7 % YoY
    Operating incomeHK$108.1M+9,9 % YoY
    Net incomeHK$91.3M+16,2 % YoY
    Free cash flow
    EPS
    Operating cash flow
    Financials
    Income statement
    RevenueHK$213.9M
    Gross profitHK$184.6M
    Operating incomeHK$108.1M
    Net incomeHK$91.3M
    Margins
    Gross margin86.3%
    Operating margin50.5%
    Net margin42.7%
    FCF margin
    Balance sheet
    Total assetsHK$828.4M
    Total liabilitiesHK$105.6M
    Total equityHK$722.7M
    Cash & equivalentsHK$331.3M
    Long-term debtHK$4.8M
    P&L flow · revenue → net income
    Revenue HK$213.9MOperating costs HK$105.8MTax HK$16.7MNet income HK$91.3M
    Highlights
    • Revenue HK$213.9M, −9,7% YoY
    • Operating income +9,9% YoY
    • Net income +16,2% YoY
    • Net margin 42.7%

    Valuation FY

    Market price
    HK$2,43
    Market cap
    HK$757.3M
    Enterprise value
    P/E
    8.3x
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    Net cash
    Current ratio
    Debt / equity
    ROA
    ROE
    Cash conversion
    CapEx / revenue
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskUnknown

    Benchmarks vs cohort

    No cohort benchmark data available for this issuer yet.

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Market Cap
      market_price * shares_outstanding_diluted
    Source documents
    • Pak Fah Yeow International Ltd Market data — financials · 2026-05-26
    • Pak Fah Yeow International Ltd Market data — analyst estimates · 2026-05-26

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    0239.HKCanonical
    HKEX · HKD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskUnknown

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2009-04-22 16:37 UTCEARNINGSAnnual results — FY 2009 Revenue HKD 213.9M · Net HKD 91.3M
    2008-04-23 11:16 UTCEARNINGSAnnual results — FY 2008 Revenue HKD 236.8M · Net HKD 78.6M
    2007-04-19 14:03 UTCEARNINGSAnnual results — FY 2007 Revenue HKD 259.2M · Net HKD 105.0M
    2006-04-20 17:09 UTCEARNINGSAnnual results — FY 2006 Revenue HKD 147.2M · Net HKD 30.0M
    2005-04-19 18:15 UTCEARNINGSAnnual results — FY 2005 Revenue HKD 139.8M · Net HKD 38.2M
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage